Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2 (1 Suppl 1), 1-16

Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia

No authors listed

Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia

No authors listed. Gastroenterol Hepatol (N Y).

Figures

Figure 1.
Figure 1.
Thymalfasin has both immunomodulatory functions and direct antiviral activities that enable the immune system to combat chronic HBV infection.
Figure 2.
Figure 2.
CAT analysis of the effect of thymalfasin on MHC class I expression in rat thyroid FRTL-5 cells. Thymalfasin is associated with an increase in the expression of MHC class I.
Figure 3.
Figure 3.
Rates of complete response to thymalfasin in a study comparing a 6-month regimen, a 12-month regimen, and placebo in the treatment of chronic HBeAg-positive HBV infection, showing delay of response.
Figure 4.
Figure 4.
Response rates at 2 dose levels from a phase III clinical trial of thymalfasin, showing serologic status at 18 months (end of study).
Figure 5.
Figure 5.
Long-term responses in a 3-arm nonrandomized trial for HBeAg-negative chronic HBV infection. Responses were superior with thymalfasin plus IFN-α vs standard therapy.
Figure 6.
Figure 6.
Combination treatment of thymalfasin plus lamivudine provides enhanced responses over lamivudine monotherapy in patients with chronic HBV infection.
Figure 7.
Figure 7.
Virologic response by genotype at week 12 of the EPIC3 study.
Figure 8.
Figure 8.
Thymalfasin in the treatment of chronic hepatitis C: median HCV RNA reduction from baseline.

Similar articles

See all similar articles

LinkOut - more resources

Feedback